The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
=== Osteological specimens === Museum collections, especially those of natural history, may contain human osteological specimens such as individual bones, bone fragments, entire skeletons, and teeth from both ancient and contemporary sources. Reconstruction of bone fragments should be conducted with great care and consideration. Due to the porous nature of bones, few adhering substances can be used on bone with an adequate level of reversibility, which is a key factor of conservation treatments.
Hypoglycemia Epinephrine (via β2, α2, and α1 adrenergic receptors) Arginine Alanine (often from muscle-derived pyruvate/glutamate transamination (see alanine transaminase reaction). Acetylcholine Cholecystokinin Gastric inhibitory polypeptide Gastrin Secretion of glucagon is inhibited by:
Prolactin receptors are present in the mammillary glands, ovaries, pituitary glands, heart, lung, thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus, skeletal muscle, skin and areas of the central nervous system. When prolactin binds to the receptor, it causes it to dimerize with another prolactin receptor. This results in the activation of Janus kinase 2, a tyrosine kinase that initiates the JAK-STAT pathway. Activation also results in the activation of mitogen-activated protein kinases and Src kinase. Human prolactin receptors are insensitive to mouse prolactin.
=== Pulmonary hypertension === While sildenafil improves some markers of disease in people with pulmonary arterial hypertension, it does not appear to affect the risk of death or serious side effects.
The two substrates of this enzyme are D-glucose and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are glucono-δ-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-glucose:NADP+ 1-oxidoreductase. Other names in common use include nicotinamide adenine dinucleotide phosphate-linked aldohexose, dehydrogenase, NADP+-linked aldohexose dehydrogenase, NADP+-dependent glucose dehydrogenase, and glucose 1-dehydrogenase (NADP+).
Sources: en.wikipedia.org
=== Humans === The cycling of and excretion of urea by the kidneys is a vital part of mammalian metabolism. Besides its role as carrier of waste nitrogen, urea also plays a role in the countercurrent exchange system of the nephrons, that allows for reabsorption of water and critical ions from the excreted urine. Urea is reabsorbed in the inner medullary collecting ducts of the nephrons, thus raising the osmolarity in the medullary interstitium surrounding the thin descending limb of the loop of Henle, which makes the water reabsorb. By action of the urea transporter 2, some of this reabsorbed urea eventually flows back into the thin descending limb of the tubule, through the collecting ducts, and into the excreted urine. The body uses this mechanism, which is controlled by the antidiuretic hormone, to create hyperosmotic urine — i.e., urine with a higher concentration of dissolved substances than the blood plasma. This mechanism is important to prevent the loss of water, maintain blood pressure, and maintain a suitable concentration of sodium ions in the blood plasma. The equivalent nitrogen content (in grams) of urea (in mmol) can be estimated by the conversion factor 0.028 g/mmol. Furthermore, 1 gram of nitrogen is roughly equivalent to 6.25 grams of protein, and 1 gram of protein is roughly equivalent to 5 grams of muscle tissue. In situations such as muscle wasting, 1 mmol of excessive urea in the urine (as measured by urine volume in litres multiplied by urea concentration in mmol/L) roughly corresponds to a muscle loss of 0.67 grams.
=== Affinity-based proteome analysis tools === The definition of TDP includes a requirement to identify the "protein", either as a distinct proteoform or ORF product. While this is most typically achieved using a mass spectrometer to fragment ions, from either intact proteoforms or peptides of resolved proteoforms, it is also possible to identify and quantify canonical "proteins" using affinity-based reagents, such as O-link and SomaScan which use antibodies or aptamers, respectively. The generic term "protein" is used here because it is unclear whether these reagents identify certain proteoforms or a variety of proteoforms from the same ORF product. These methods thus produce similar, yet different, information relative to each other and to proteogenomic BUP approaches using LC/MS/MS. Because of the claimed (i) "depth" of these assays in terms of identifying canonical protein sequences; and (ii) apparent ability to quantify changes in the abundance of those proteins in samples that can be problematic for other proteomics technologies (e.g. plasma and serum), these technologies have become popular in studies having enormous sample numbers that are impossible to directly address by other proteomics technologies. However, the substantial lack of correlation between these technologies, as well as with other established proteomics technologies, needs to be addressed, along with fully characterizing the exact proteoforms that these reagents are identifying. This will thus also require transparent verification of the quality and selectivity of any antibodies and aptamers used.
Recent studies have shown the presence of microplastics in breast milk, often leading to exposures in very young children. While it has already been established that chemicals such as flame retardants and pesticides have been detected in breast milk, knowledge about microplastics is limited in comparison. A 2022 study detected microplastics in 26 of 34 breast milk samples, with particles ranging from 2 to 12μm in size, raising concerns about infant exposure during critical developmental windows. No safe or harmful exposure level for microplastics has been established, and exposure to MNPs during early developmental stages has raised questions about possible developmental effects or other health issues later in life. Additionally, breast pumps and breastmilk storage bags are frequently made of plastic. Freezing liquid in a plastic container and then heating it up (the "freeze-thaw cycle") has been shown to increase the presence of microplastics. Similar results have been seen from heating plastic reusable food containers in a microwave, showing the increased release of MNPs. It is not recommended that frozen breastmilk ever be thawed in a microwave.
The first MP, installed at Yale in 1963, operated consistently at 10–11 megavolts; a later installation at Strasbourg reached 18. At these energies, electron stripping becomes highly efficient. A uranium ion passing through the terminal can lose more than 20 electrons, enabling heavy-ion fusion experiments impossible with earlier machines. Advances in gamma-ray spectroscopy combined with MP tandems enabled precision measurements of nuclear structure. HVEC manufactured 10 MP units between 1965 and 1973 for institutions including the University of Minnesota, Chalk River, and the Max Planck Institute in Heidelberg. The XTU ("Holy Roman Emperor") was designed for superheavy element synthesis. Theoretical models predicted an "island of stability" beyond element 110 where nuclei would resist rapid decay. The XTU's 20-megavolt rating would accelerate uranium ions to nearly one billion electron volts—enough to overcome Coulomb barriers in heavy-element fusion. Two prototypes operated solely on a test basis at Burlington before the project was cancelled. One later sold to Italy's national laboratory at Legnaro in 1979.
Sources: en.wikipedia.org
== Sources and composition == Silk is not a single substance but a family of fibrous proteins spun by several different animals, and the silks used as biomaterials differ both in their origin and in the proteins they contain.
=== Supercritical water hydrolysis === Supercritical hydrolysis is a method of converting all biomass polysaccharides as well the associated lignin into low molecular compounds by contacting with water alone under supercritical conditions. The supercritical water, acts as a solvent, a supplier of bond-breaking thermal energy, a heat transfer agent and as a source of hydrogen atoms. All polysaccharides are converted into simple sugars in near-quantitative yield in a second or less. The aliphatic inter-ring linkages of lignin are also readily cleaved into free radicals that are stabilized by hydrogen originating from the water. The aromatic rings of the lignin are unaffected under short reaction times so that the lignin-derived products are low molecular weight mixed phenols. To take advantage of the very short reaction times needed for cleavage a continuous reaction system must be devised. The amount of water heated to a supercritical state is thereby minimized.
The first season of Beast Games, a reality competition show created by Jimmy "MrBeast" Donaldson was first released on Amazon Prime Video on December 19, 2024 and concluded on February 13, 2025. Jeffrey Randall Allen won the season, defeating Twana Barnett. Allen won a total grand prize of $10,000,000.
=== Decline === By 1987, the label began to see its commercial fortunes decline. Contributing to the decline were A&R problems with Shalamar, primarily, maintaining the group's identity and momentum as former members Hewett and Watley had departed and were having successful solo careers on other labels. The shifting musical directions of R&B, dance and popular music in general in the late 1980s and early 1990s also contributed to their decline.
Principal cells: columnar cells that, with the basal cells, form the majority of the epithelium. In the caput (head) region, these cells have long stereocilia that are tuft-like extensions that project into the lumen. The stereocilia are much shorter in the cauda (tail) segment. They also secrete carnitine, sialic acid, glycoproteins, and glycerylphosphorylcholine into the lumen. Basal cells: shorter, pyramid-shaped cells, which contact the basal lamina but taper off before their apical surfaces reach the lumen. These are thought to be undifferentiated precursors of principal cells. Apical cells: predominantly found in the head region Clear cells: predominant in the tail region Intraepithelial lymphocytes: distributed throughout the tissue. Intraepithelial macrophages
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.